ArticleIJID regions2026
Cost-effectiveness of routine influenza vaccination program for individuals aged 65 years and older in Japan: Substituting standard-dose inactivated vaccine with high-dose inactivated vaccine.
Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: We evaluated cost-effectiveness of influenza immunization programs for protection of Japanese elderly (aged ≥65 years) from influenza-related diseases by comparing high-dose inactivated influenza vaccine (HD-IIV3) to standard vaccines (SD-IIV3). Methods: Incremental cost-effectiveness ratio (ICER) from payers' perspective was calculated. Variables used in the model were either calculated or extracted from literature. Quality-adjusted life years (QALYs) was used as measure of effectiveness. Cost per dose of HD vaccine was assumed to be four times of SD (JPY 1500/US$ 10). Results: In comparison to SD, HD gained more QALYs and reduced disease treatment costs, but these reduced costs did not offset vaccination cost. ICER for those aged ≥65 years was JPY 7,352,458/ US$ 49,016 per QALY, higher than the willingness-to-pay (WTP) threshold of JPY 5,000,000/US$ 33,333 per QALY. While ICER was JPY 50,477,31/US$ 33,652 for those aged ≥75 years. One-way sensitivity analysis revealed that relative vaccine effect against laboratory-confirmed influenza of HD to SD influenced the ICER the most. Monte Carlo simulations revealed that the probability of an ICER below WTP threshold was 20.9%. Conclusions: For a WTP of JPY 5,000,000/US$ 33,333 per QALY gained, if the price of HD was four times the current vaccine, the seasonal HD-IIV3 vaccination program was not cost-effective for those aged ≥65 years, while was cost-effective for those aged ≥75 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.